COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD) (Bacteriophage)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01617122
Recruitment Status : Unknown
Verified July 2012 by University of South Florida.
Recruitment status was:  Recruiting
First Posted : June 12, 2012
Last Update Posted : July 17, 2012
Information provided by (Responsible Party):
University of South Florida

Brief Summary:
This protocol is designed to ascertain whether the bacteriophage 0X174 neoantigen is safe and effective as an antigen used in the evaluation of primary and secondary immune responses. Bacteriophage 0X174 is given intravenously 2 billion PFU/Kg of body weight; small blood specimens of 3-5 ml (about 1 teaspoon) are collected after 15 minutes, 7 days, 14 days, and 28 days. Blood is collected at intervals following the administration of the bacteriophage and the number of phage/ml is determined by the agar overlay method using suspension of E. coli C and serially diluted patient's serum. Phage-specific IgG and IgM are measured by neutralization assay. Capacity of switch from IgM to IgG is determined.

Condition or disease Intervention/treatment Phase
Primary Immune Deficiency Diseases Biological: Bacteriophage OX174 Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: To Evaluate Bacteriophage OX174 Antigen as a Useful Immunogen in Patients With Immune Deficiency
Study Start Date : October 1995
Estimated Primary Completion Date : December 2015
Estimated Study Completion Date : December 2015

Arm Intervention/treatment
Experimental: Bacteriophage
Subjects receive bacteriophage vaccinations and blood draws
Biological: Bacteriophage OX174
Give first dose of bacteriophage (2 x 109 PFU/kg body weight (0.02 ml/kg)) at visit one. Obtain labs prior to vaccine, 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. 6 weeks after 1st vaccine, obtain blood, give 2nd dose of bacteriophage, obtain labs 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. Selected patients may receive a tertiary vaccine.

Primary Outcome Measures :
  1. Evidence of capacity of switch from IgM to IgG. [ Time Frame: 12 weeks ]
    Blood samples are obtained after each immunizition of Bacteriophage.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 85 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. subject/parent or guardian willing to sign consent and adhere to study schedule
  2. known or suspected primary immune deficiency

Exclusion Criteria:

  1. pregnancy
  2. breastfeeding
  3. unwilling to sign consent or adhere to study schedule
  4. < 2 yrs of age or > 85 yrs of age
  5. previous reaction to vaccine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01617122

Layout table for location contacts
Contact: Carla Duff, RN BSN CCRP 727-553-3515
Contact: Amy Kramer 727-553-1258

Layout table for location information
United States, Florida
University of South Florida Recruiting
St. Petersburg, Florida, United States, 33701
Contact: Carla Duff, RN BSN CCRP    727-553-3515   
Contact: Amy Kramer    727-553-1258   
Sponsors and Collaborators
University of South Florida
Layout table for investigator information
Principal Investigator: John W Sleasman, MD University of South Florida
Layout table for additonal information
Responsible Party: University of South Florida Identifier: NCT01617122    
Other Study ID Numbers: ACH 03-0120
First Posted: June 12, 2012    Key Record Dates
Last Update Posted: July 17, 2012
Last Verified: July 2012
Keywords provided by University of South Florida:
antibody deficiency
recurrent infections
Additional relevant MeSH terms:
Layout table for MeSH terms
Deficiency Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Nutrition Disorders